Tags : Pieris

Weekly Snapshot

PharmaShots Weekly Snapshots (Apr 26 – 30, 2021)

BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority Review, nivolumab, Muscle Invasive Urothelial Carcinoma Janssen Reports MAA Submission to EMA for Cilta-cel to Treat Relapsed/ Refractory Multiple Myeloma Published: Apr 30, 2021 | […]Read More


Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

Shots: Pieris to receive $10M upfront and is eligible to receive $353M in development, regulatory, and commercial based milestones along with royalties on sales of PRS-342. Pieris will also contribute an undisclosed amount for manufacturing activities Boston to get exclusive worldwide rights to develop PRS-342 and will be primarily responsible for the development of the […]Read More